CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 138 filers reported holding CATALYST PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $350,700 | -13.0% | 30,000 | 0.0% | 0.04% | -10.6% |
| Q2 2023 | $403,200 | -18.9% | 30,000 | 0.0% | 0.05% | -23.0% |
| Q1 2023 | $497,400 | -10.9% | 30,000 | 0.0% | 0.06% | -12.9% |
| Q4 2022 | $558,000 | +44.9% | 30,000 | 0.0% | 0.07% | +32.1% |
| Q3 2022 | $385,000 | +83.3% | 30,000 | 0.0% | 0.05% | +12.8% |
| Q2 2022 | $210,000 | -15.7% | 30,000 | 0.0% | 0.05% | +56.7% |
| Q1 2022 | $249,000 | -8.1% | 30,000 | -25.0% | 0.03% | -9.1% |
| Q4 2021 | $271,000 | +27.8% | 40,000 | 0.0% | 0.03% | +17.9% |
| Q3 2021 | $212,000 | -7.8% | 40,000 | 0.0% | 0.03% | -45.1% |
| Q2 2021 | $230,000 | +25.0% | 40,000 | 0.0% | 0.05% | +13.3% |
| Q1 2021 | $184,000 | +37.3% | 40,000 | 0.0% | 0.04% | +28.6% |
| Q4 2020 | $134,000 | +12.6% | 40,000 | 0.0% | 0.04% | -5.4% |
| Q3 2020 | $119,000 | -35.7% | 40,000 | 0.0% | 0.04% | -42.2% |
| Q2 2020 | $185,000 | – | 40,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $2,458 | 7.14% |
| GABLES CAPITAL MANAGEMENT INC. | 409,080 | $6,782,546 | 4.74% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 10,355,099 | $171,687,541 | 3.83% |
| JW Asset Management, LLC | 563,392 | $9,341,039 | 3.58% |
| Quantedge Capital Pte Ltd | 324,700 | $5,383,526 | 2.10% |
| Paradiem, LLC | 236,628 | $3,923,292 | 1.22% |
| SummerHaven Investment Management, LLC | 100,592 | $1,667,815 | 0.97% |
| Capital Impact Advisors, LLC | 46,096 | $764,272 | 0.94% |
| Yorktown Management & Research Co Inc | 50,000 | $829,000 | 0.89% |
| Seaport Global Advisors, LLC | 15,598 | $258,615 | 0.82% |